ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Women’s Health Initiative Trial Produced $37.1 Billion in Returns

May 9, 2014

Ten Cooperative Group Chairs Propose Eight “Guiding Principles” For Change

May 20, 2011

Wyngaarden Recommendation On New Director Due Nov. 1o; Five Staff Members Nominated

November 4, 1988

CPRIT Awards 32 Grants

November 21, 2014

FDA, NCI Seek Compromise On Survival Endpoints

June 16, 1989

What Is and Isn’t a Crime in Texas: CPRIT Official Indicted For Skipping Peer Review

December 13, 2013